Unlock stock picks and a broker-level newsfeed that powers Wall Street.
66.94
-4.50
(-6.31%)
As of 2:28:18 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Anish Bhatnagar M.D. | President, CEO, COO & Director | 1.06M | -- | 1970 |
| Mr. James H. MacKaness | CFO & Compliance Officer | 640k | -- | 1964 |
| Ms. Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs | 493k | -- | 1966 |
| Mr. Jesse Schumaker | General Counsel | -- | -- | -- |
| Ms. Lauren Budesheim | Vice President of People | -- | -- | -- |
| Ms. Kristen Yen M.S. | Senior Vice President of Clinical Operations | 317.19k | -- | 1969 |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development | -- | -- | -- |
| Ms. Meredith Manning M.B.A. | Chief Commercial Officer | -- | -- | 1973 |
| Dr. Michael Huang M.D. | Senior Vice President of Clinical Development | -- | -- | 1974 |
| Dr. Mitchell Nagao M.B.A., Pharm.D. | Senior Vice President of Medical Affairs | -- | -- | -- |
Soleno Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 92
Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Corporate Governance
Soleno Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 7; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 7, 2025 at 8:00 PM UTC - May 12, 2025 at 8:00 PM UTC
Soleno Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
CORT Corcept Therapeutics Incorporated
91.75
-19.67%
PRTG Portage Biotech Inc.
8.21
-11.24%
LXRX Lexicon Pharmaceuticals, Inc.
0.4781
+3.74%
OSRH OSR Holdings, Inc.
1.8300
-2.66%
TNXP Tonix Pharmaceuticals Holding Corp.
17.00
-4.90%
MIST Milestone Pharmaceuticals Inc.
0.7500
-6.26%
OCEA Ocean Biomedical, Inc.
0.0508
-5.93%
DRMA Dermata Therapeutics, Inc.
1.0400
-3.70%
DBVT DBV Technologies S.A.
6.37
-6.60%
PCVX Vaxcyte, Inc.
32.73
-13.32%